GSK ups lung drug bet by buying more of Theravance

LONDON (Reuters) - GlaxoSmithKline bet another $212.9 million on the success of lung drug Relovair on Monday by raising its stake in U.S. biotech firm Theravance - its partner on the new medicine -...

Source: http://feeds.reuters.com/~r/reuters/dealsNews/~3/tlc28_ydhV0/us-gsk-idUSBRE8310GW20120402

make money online money save money travel cheap travel destinations top news